**7. Associated treatments in ANCA-associated vasculitis**

Management of AAV includes other therapeutic measures such as local and/ or surgical treatment of ENT manifestations in GPA and EGPA (nasal irrigations,


*GPA: granulomatosis with polyangiitis, MPA: microscopic polyangiitis, EGPA: eosinophilic granulomatosis with polyangiitis, GCs: glucocorticoids MTX: methotrexate, AZA: azathioprine, MMF: mycophenolate mofetil, CYC: cyclophosphamide, MEP: mepolizumab, ENT: ear nose throat.*

#### **Table 4.**

*Recommendations/statements for the management of ANCA vasculitis [24].*

*Current Treatment of ANCA Vasculitis DOI: http://dx.doi.org/10.5772/intechopen.110375*

nebulizations, polyposis resection …), kinesitherapy and symptomatic treatments for neuropathic symptoms and hemodialysis in end-stage renal disease. In addition, complications related to the long-term use of corticosteroids should be managed (hypertension, diabetes …) [28]**.**

Cotrimoxazole (trimethoprim/sulfamethoxazole) is highly recommended in AAV and should be discussed in case of lymphopenia. Especially in GPA, it prevents from pneumocystis and has a role in remission maintenance of this vasculitis (**Table 4**).
